Skip to main content

NovaBay Pharmaceuticals Announces Expansion of DERMAdoctor Picture Porefect Collection with Launch of 15% Niacinamide Pore Minimizing Serum

New super-charged serum helps men and women minimize the size of enlarged facial pores

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the newest addition to the DERMAdoctor® Picture Porefect® collection: 15% Niacinamide Pore Minimizing Serum. This new, high-potency formulation minimizes the size of visible facial pores while delivering free-radical-neutralizing antioxidants and collagen-supporting agents to reduce blackheads, skin discoloration, rough skin, acne, and oily or combination skin.

This press release features multimedia. View the full release here:

DERMAdoctor Picture Porefect 15% Niacinamide Pore Minimizing Serum (Photo: Business Wire)

DERMAdoctor Picture Porefect 15% Niacinamide Pore Minimizing Serum (Photo: Business Wire)

“The appearance of enlarged pores is a concern of many women who strive to achieve their most beautiful complexion,” said NovaBay Chief Product Officer Audrey Kunin, MD, a board-certified dermatologist. “Our new supercharged 15% Niacinamide Pore Minimizing Serum helps neutralize the effects of environmental stressors such as sunlight, pollution and toxins, leaving skin looking and feeling radiant. Gentler than retinol, niacinamide-based products can be used daily. In fact, just five drops of this highly concentrated serum on clean, dry facial skin twice a day can achieve a complexion free of large or congested pores, redness and skin discoloration, with or without makeup.”

Picture Porefect 15% Niacinamide Pore Minimizing Serum is formulated with proven dermatological ingredients including the antioxidant niacinamide (a form of vitamin B3) to help detoxify and cleanse pores and reduce inflammation, vitamin C to support the dermal collagen that keeps pores tight, zinc to help clarify pore-plugging skin oils, and peptides to help dermal collagen tighten pores and improve the appearance of fine lines and wrinkles. The serum is now available in a 1 fluid ounce pump bottle on and for $42.

All DERMAdoctor products are scientifically formulated to provide measurable results for common skincare concerns that have been largely overlooked by the beauty industry and are hypoallergenic, non-irritating, non-drying, pH balanced and free of synthetic fragrance and dye. DERMAdoctor sells its products through major retailers such as Macy’s, QVC, and, as well as through digital beauty retailers including SkinStore, and DERMAdoctor products are also available internationally through select distributors and retailers.

About NovaBay Pharmaceuticals, Inc.:

NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells scientifically created and clinically proven eyecare and skincare products. Avenova® is the most prescribed antimicrobial lid and lash spray and DERMAdoctor® is a premium skincare brand offering more than 30 dermatologist-developed skincare products sold through traditional domestic retailers, digital beauty channels and international distributors.

NovaBay Pharmaceuticals Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding current and future product offerings, marketing efforts, and any future revenue that may result from selling such products, as well as generally the Company’s expected future financial results (and ability to continue as a going concern) and the impact of a reverse stock split. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings with the SEC, especially under the heading “Risk Factors,” and in the Preliminary Proxy Statement filed by NovaBay with the SEC, especially under the heading “Proposal Two: The Reverse Stock Split Proposal — Risks Relating to the Reverse Stock Split.” The forward-looking statements in this press release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay Informed on NovaBays Progress

Like us on Facebook

Follow us on Twitter

Connect with NovaBay on LinkedIn

Visit NovaBay’s Website

Avenova Purchasing Information

For NovaBay Avenova purchasing information:

Please call 800-890-0329 or email

DERMAdoctor Purchasing Information

For DERMAdoctor purchasing information:

Please call 877-337-6237 or email


NovaBay Contact

Justin Hall

Chief Executive Officer and General Counsel


Investor Contact

LHA Investor Relations

Jody Cain


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.